Baidu
map

女性缺血性卒中患者发生卒中肺炎的风险较低

2016-07-10 MedSci MedSci原创

背景:脑缺血卒中后的感染并发症是常见的,导致神经功能恶化,功能预后不良,死亡率较高。男性和女性脑缺血的局部和全身炎症反应不同,但卒中后的感染易感的性别差异了解较少。这篇研究旨在比较急性缺血性脑卒中(AIS)医院获得性败血症和急性肺炎风险的性别差异。材料与方法:这是一项对2010-2011年加利福尼亚医院数据库的回顾性二次分析。应用国际疾病分类第九版(ICD-9代码)来确定AIS发生。主要预后是医院

背景:脑缺血卒中后的感染并发症是常见的,导致神经功能恶化,功能预后不良,死亡率较高。男性和女性脑缺血的局部和全身炎症反应不同,但卒中后的感染易感的性别差异了解较少。这篇研究旨在比较急性缺血性脑卒中(AIS)医院获得性败血症和急性肺炎风险的性别差异。

材料与方法:这是一项对2010-2011年加利福尼亚医院数据库的回顾性二次分析。应用国际疾病分类第九版(ICD-9代码)来确定AIS发生。主要预后是医院获得性感染或肺炎,也使用ICD-9代码确定。应用多因素Logistic回归分析,校正基线特征和共发病后,性别与医院获得性败血症和肺炎的关系。

结果:共有91643例AIS患者纳入分析,1027例患者发生医院获得性败血症1225例患者发生医院获得性肺炎。无感染的病死率为4.6%;医院获得性感染与脓毒症(32.7%)和肺炎(21.9%)死亡率较高相关。女性(和男性)和较低的校正医院获得性感染和败血症( OR: 0.74;95%CI: 0.65-0.84)和肺炎(OR 0.69;95 %CI:0.62 – 0.78)。校正年龄后,这种差异仍存在。不管是医院获得性败血症和肺炎,性别不影响其死亡率。

结论:女性与AIS后医院获得性败血症和肺炎风险较低相关。需要进一步的研究,以确定临床观察的机制。

原始出处:


Colbert JF, Traystman RJ, et al. Sex-Related Differences in the Risk of Hospital-Acquired Sepsis and Pneumonia Post Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2016 Jun 28.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010351, encodeId=07402010351fa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Dec 02 21:48:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806093, encodeId=02b1180609397, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 17 18:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892771, encodeId=84261892e716e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 25 17:48:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720122, encodeId=fc181e2012290, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 26 15:48:00 CST 2016, time=2016-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145842, encodeId=95cd145842cd, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:15:02 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010351, encodeId=07402010351fa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Dec 02 21:48:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806093, encodeId=02b1180609397, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 17 18:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892771, encodeId=84261892e716e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 25 17:48:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720122, encodeId=fc181e2012290, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 26 15:48:00 CST 2016, time=2016-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145842, encodeId=95cd145842cd, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:15:02 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010351, encodeId=07402010351fa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Dec 02 21:48:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806093, encodeId=02b1180609397, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 17 18:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892771, encodeId=84261892e716e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 25 17:48:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720122, encodeId=fc181e2012290, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 26 15:48:00 CST 2016, time=2016-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145842, encodeId=95cd145842cd, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:15:02 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010351, encodeId=07402010351fa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Dec 02 21:48:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806093, encodeId=02b1180609397, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 17 18:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892771, encodeId=84261892e716e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 25 17:48:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720122, encodeId=fc181e2012290, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 26 15:48:00 CST 2016, time=2016-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145842, encodeId=95cd145842cd, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:15:02 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2010351, encodeId=07402010351fa, content=<a href='/topic/show?id=9cf7e9360d2' target=_blank style='color:#2F92EE;'>#缺血性卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79360, encryptionId=9cf7e9360d2, topicName=缺血性卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Fri Dec 02 21:48:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806093, encodeId=02b1180609397, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Sep 17 18:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892771, encodeId=84261892e716e, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Apr 25 17:48:00 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720122, encodeId=fc181e2012290, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Sat Nov 26 15:48:00 CST 2016, time=2016-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145842, encodeId=95cd145842cd, content=赞了,认真探究、学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 22:15:02 CST 2016, time=2016-10-11, status=1, ipAttribution=)]
    2016-10-11 ylzr123

    赞了,认真探究、学习。

    0

相关资讯

PLoS One:急性缺血性脑卒中患者,高血浆hsCRP水平与不良临床预后独立相关

背景:尽管由于脑梗死后炎症反应使得血浆C反应蛋白(CRP)升高,但急性缺血性卒中后的C反应蛋白与临床预后的关系仍不明朗。本研究旨在探讨血浆高敏C反应蛋白(hsCRP)水平是否独立于传统的危险因素和急性卒中后感染,与临床结局相关。方法:研究者前瞻性纳入3653例首发缺血性脑卒,这些患者功能独立,并且症状开始24h内入院。入院时检测血浆hsCRP水平,将血浆hsCRP水平分为四分位数。采用Logist

J Stroke Cerebrovasc Dis:他汀药物可降低缺血性卒中感染发生的风险

目标:他汀类药物独立于其降脂作用具有免疫调节的作用和外周抗炎的特性。在临床研究中,这些性质是否降低卒中后感染风险尚不确定。研究者评估18岁以上住院的缺血性卒中患者,他汀类暴露对卒中后感染发生的风险。材料与方法:对急性护理医院电子病历进行回顾性分析。将患者分配到暴露队列,感染前应用他汀类药物,应用他汀药物治疗但未感染。未暴露队列包括未应用他汀类药物,或感染后应用他汀类药物。校正卒中后感染的危险因素条

Stroke:PASS量表可预测大动脉闭塞性缺血性卒中

背景:研究者设计并验证一个简单的院前卒中量表识别紧急大血管闭塞(ELVO)性缺血性脑卒中,并且与其他已经发表的预测ELVO的量表进行比较。方法:国家历史测试队列中的3127例患者,确认再灌注治疗前颅内血管状态(血管造影)。美国国立卫生院卒中量表(NIHSS)是预测颅内大动脉闭塞价值最高量表,确定院前符合预定标准的最优组合是可行的。比较院前急性卒中严重程度(PASS)量表和ELVO其他已发表的量表的

Stroke: 缺血性卒中血管内治疗适应症的预测因子

背景:血管内治疗(EVT)是大血管闭塞性卒中新的标准化的治疗。研究者旨在确定综合卒中中心符合静脉溶栓(IVT)和EVT条件的患者。并且,推导预测适合EVT治疗的预测因子。方法:从卒中中心登记的患者(2003-2014),入院24小时内常规检查,根据美国心脏协会/美国卒中协会(AHA/ASA)选择出能够确定IVT和EVT适应症的所有数据。此外,从随机对照试验和临床实践中选出较少限制性的标准。IVT(

Stroke:心肌梗死幸存者,卒中发生的长期风险(30年队列研究)

背景:心肌梗死(MI)后改善生存可增加心肌梗死后卒中的风险。研究者调查了与一般人群相比,心肌梗死的患者发生缺血性卒中,脑出血(ICH),蛛网膜下腔出血(SAH)的风险。方法:研究者使用丹麦的医疗登记记录进行了一项全国性的以人群为基础的队列研究。在1980至2009年间,研究者确定了第一次住院诊断为心肌梗死的患者,并形成了按照性别和年龄匹配的对照组。研究者计算累积卒中风险和校正后的卒中RR值及95%

J Stroke Cerebrovasc Dis: 脑实质血肿2型与缺血性卒中溶栓后24h恶化相关

背景:静脉溶栓治疗可以改善急性缺血性卒中(AIS)神经功能预后,但存在出血性转化(HT)的风险。症状性脑出血(ICH)的目前的定义:有一定程度的相关的神经系统恶化。然而,早期继发性脑出血的有害影响,也可能表现为减少神经系统功能的改善。本研究旨在探讨是不同的影像类型的HT和溶栓后24小时神经功能改善程度之间是否独立相关。方法:这项研究是对AIS溶栓病例的中心数据库进行回顾性分析。校正潜在的混杂因素后

Baidu
map
Baidu
map
Baidu
map